Pancreatic polypeptide family motifs and polypeptides comprising the same

• US 8,603,969 B2
• Filed: 02/11/2005
• Issued: 12/10/2013
• Est. Priority Date: 02/11/2004
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC), Amylin Pharmaceuticals LLC (Bristol-Myers Squibb Company)
• Inventors: Levy, Odile Esther, Jodka, Carolyn M., Ghosh, Soumitra S., Parkes, David G., Pittner, Richard A., D'Souza, Lawrence J., Ahn, John S., Prickett, Kathryn S.
• Primary Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US11/055,098
• Publication Number:
  US 20060094653A1
• Time in Patent Office: 3,224 Days
• Field of Search: None
• US Class Current: 514/5.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif. Methods of using the PPF polypeptides of the invention, and pharmaceutical compositions including the PPF polypeptides of the invention are also disclosed.

Claims

1. A PPF polypeptide, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:

54 through SEQ ID NO;

87.

2. A PPF polypeptide, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

131 to 132, 150 to 156, 160, 180 to 186, 207 to 210, 219 to 220, 252, 265, 275, 281, 286, 287, 292 to 293, and 313.

3. A PPF polypeptide, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

187 to 197.